‘Reassuring’ GI event risks for arthritis patients on NSAIDs

Clinically significant gastrointestinal events occur at a "reassuringly low" rate in patients with arthritis who are taking NSAIDS and a PPI, according to results from a large trial.

Secondary outcomes from the PRECISION trial, designed to determine the cardiovascular safety of celecoxib compared to ibuprofen and naproxen, showed less than 1% of 24,000 patients experienced a GI event such as bleeding, obstruction, perforation, symptomatic ulcers or iron deficiency anaemia.

In the Pfizer-funded trial, patients were randomly allocated to receive celecoxib 100-200mg twice daily, ibuprofen